Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for alcohol use and depression in a patient with oropharyngeal carcinoma
TCTR20180417001Phase 1Terminated
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxytocin in alcohol use disorder (AUD), major depressive disorder (MDD) and oropharyngeal cancer, sponsored by none. Primary endpoints: Alcohol consumption reduction and Depressive symptom reduction. Started Jun 2014; status: terminated.
02
Drugs
oxytocin
03
Conditions
alcohol use disorder (AUD)major depressive disorder (MDD)oropharyngeal cancer
Beyond the preview
Go deeper on TCTR20180417001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180417001.